Free Trial

NovaBay Pharmaceuticals (NBY) Competitors

NovaBay Pharmaceuticals logo
$0.67 +0.02 (+3.24%)
As of 03:57 PM Eastern

NBY vs. PRPH, ALLR, MTEX, EQ, ERNA, PMN, LPTX, BFRG, SNPX, and NEUP

Should you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Mannatech (MTEX), Equillium (EQ), Ernexa Therapeutics (ERNA), Promis Neurosciences (PMN), Leap Therapeutics (LPTX), Bullfrog AI (BFRG), Synaptogenix (SNPX), and Neuphoria Therapeutics (NEUP). These companies are all part of the "pharmaceutical products" industry.

NovaBay Pharmaceuticals vs. Its Competitors

NovaBay Pharmaceuticals (NYSE:NBY) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

In the previous week, ProPhase Labs had 4 more articles in the media than NovaBay Pharmaceuticals. MarketBeat recorded 4 mentions for ProPhase Labs and 0 mentions for NovaBay Pharmaceuticals. ProPhase Labs' average media sentiment score of 0.63 beat NovaBay Pharmaceuticals' score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the news media.

Company Overall Sentiment
NovaBay Pharmaceuticals Neutral
ProPhase Labs Positive

23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 0.1% of NovaBay Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ProPhase Labs has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. ProPhase Labs' return on equity of -184.38% beat NovaBay Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NovaBay Pharmaceuticals-102.72% -7,293.78% -158.41%
ProPhase Labs N/A -184.38%-64.59%

NovaBay Pharmaceuticals currently has a consensus price target of $0.85, indicating a potential upside of 26.41%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe NovaBay Pharmaceuticals is more favorable than ProPhase Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NovaBay Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
ProPhase Labs
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

NovaBay Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.41, indicating that its share price is 141% less volatile than the S&P 500.

NovaBay Pharmaceuticals has higher revenue and earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovaBay Pharmaceuticals$9.78M0.40-$9.64M-$53.72-0.01
ProPhase Labs$6.77M2.86-$53.36M-$1.26-0.37

Summary

NovaBay Pharmaceuticals and ProPhase Labs tied by winning 8 of the 16 factors compared between the two stocks.

Get NovaBay Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NBY vs. The Competition

MetricNovaBay PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$3.91M$776.90M$5.70B$21.12B
Dividend YieldN/A4.84%4.69%3.60%
P/E Ratio-0.011.4028.0728.44
Price / Sales0.4025.35448.5760.38
Price / CashN/A19.5636.2222.92
Price / Book0.166.798.664.69
Net Income-$9.64M-$4.32M$3.25B$995.51M
7 Day Performance1.42%1.33%4.20%1.64%
1 Month Performance17.22%3.74%10.82%5.92%
1 Year Performance-65.34%8.18%34.70%11.50%

NovaBay Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBY
NovaBay Pharmaceuticals
1.5706 of 5 stars
$0.67
+3.2%
$0.85
+26.4%
-69.8%$3.91M$9.78M-0.0130Gap Up
PRPH
ProPhase Labs
0.3854 of 5 stars
$0.40
+10.3%
N/A-86.4%$15.18M$6.77M0.00130Gap Up
ALLR
Allarity Therapeutics
0.7302 of 5 stars
$0.97
-2.3%
N/A-81.0%$15.03MN/A0.0010Positive News
MTEX
Mannatech
1.0455 of 5 stars
$8.08
+2.8%
N/A+11.0%$14.94M$115.04M-80.80250News Coverage
Gap Down
EQ
Equillium
2.9663 of 5 stars
$0.41
-0.2%
$3.00
+624.5%
-58.4%$14.83M$41.10M-1.0640Positive News
Gap Up
ERNA
Ernexa Therapeutics
1.1012 of 5 stars
$1.96
-1.0%
N/A-92.7%$14.58M$580K-0.2410Positive News
Gap Up
PMN
Promis Neurosciences
2.9631 of 5 stars
$1.12
+154.5%
$4.33
+286.9%
-56.9%$14.39MN/A-22.405News Coverage
Analyst Revision
High Trading Volume
LPTX
Leap Therapeutics
2.1067 of 5 stars
$0.34
-1.5%
$3.38
+895.6%
-82.7%$14.26MN/A-0.2040Positive News
Gap Down
BFRG
Bullfrog AI
0.417 of 5 stars
$1.50
-0.7%
N/A-43.4%$14.22M$60K-1.854High Trading Volume
SNPX
Synaptogenix
0.0429 of 5 stars
$10.11
+7.6%
N/A+130.6%$14.05MN/A-1.004High Trading Volume
NEUP
Neuphoria Therapeutics
2.1992 of 5 stars
$7.70
+3.4%
$21.00
+172.7%
N/A$14.01M$10K0.00N/A

Related Companies and Tools


This page (NYSE:NBY) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners